Replies to post #4918 on BioCurex, Inc.(fka BOCX)

[erthang]

Good ?'s Goldseeker. I have the answer to one of them. I have a ? for you though, "Why do you care?" If this company is a sham as you imply? You divested? You obviously aren't convinced yourself. You have already shown your worth to this board as an incedible poster, making baseless untrue statements hoping for some commentary that refutes your assertions.

Anyway, to answer your ? on the upfront fee, BOCX has so much faith in the technology, they took a small upfront fee with the trade off being, a heavily backloaded deal, in which they will get substantial payments when milestones are acheived and 10 - 15% of the profits when products begin to sell with know expenditures on their side.

[bocxman]

goldseeker: let me ask you this, do you know anything about the deal parameters between BOCX and ABT other than the size of the upfront? NO. do you know how big the milestone payments are, and most importantly, the size of the royalty vig? NO.

do you realize that BOCX expressly said they back-loaded the deal? you can say "BOCX is lying about that" -- BUT THAT IS ALL YOU CAN SAY. either BOCX is lying, or they negotiated a back-loaded deal with ABT.

there are licensing deals with NO UPFRONT and a huge revenue split, there are deals with HUGE UPFRONT and no revenue share, there are deals with SMALL UPFRONT and small revenue split, etc.
who knows what BOCX negotiated? one thing's for sure, nobody here knows. i wouldn't be surprised if BOCX got a one-sided deal from ABT, but we don't know, and the important thing is that little BOCX trading on the pink sheets is one of only a few companies that you can count on ONE HAND that ABT has licensed a cancer marker from in the past 5 years or so.

clearly, this entire line of posting of yours originated from the fact that the crux of your ORIGINAL ARGUMENT about why the ABT deal is crappy was that ABT was some cancer marker licensing machine and threw RECAF in with the rest of them without doing any DD.

when i posted info that ABT had only licensed one other cancer marker in the last 18 months, you quickly avoided that point and scrambled to come up with other reasons why the deal was worthless...then you just posted some hogwash listing only 4 markers that abbott has licensed going back to 5 years ago? one of them, HUMIRA, is a therapy not a diagnostic. another one, the PSA, has been in existence for many many years. and a third one you listed, the CA family, have also been around for many many years. thank you so very much for proving my point. the fact remains they are CAREFULLY AND SELECTIVELY licensing cancer markers, as evidenced by the data you yourself posted. ...now you are clinging to the size of the upfront.

goldseeker: sell your stock if you have so little confidence in the deal.